Eventide Asset Management’s Sage Therapeutics SAGE Stock Holding History

Eventide Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-790,000	Closed	-$22.7M	–	137
2020 Q1	$22.7M	Hold	790,000	–	–	0.73%	54
2019 Q4	$57M	Hold	790,000	–	–	1.61%	18
2019 Q3	$111M	Buy	790,000 +35,000	+5%	+$5.85M	3.66%	3
2019 Q2	$138M	Sell	755,000 -50,000	-6%	-$8.53M	4.2%	3
2019 Q1	$128M	Sell	805,000 -131,000	-14%	-$19M	4.41%	2
2018 Q4	$89.7M	Buy	936,000 +442,000	+89%	+$50.6M	3.97%	3
2018 Q3	$69.8M	Buy	494,000 +124,000	+34%	+$19.1M	2.56%	5
2018 Q2	$57.9M	Buy	370,000 +120,000	+48%	+$18.8M	2.4%	4
2018 Q1	$40.3M	Buy	250,000 +65,400	+35%	+$11.1M	1.89%	12
2017 Q4	$30.4M	Buy	184,600 +25,600	+16%	+$2.48M	1.59%	21
2017 Q3	$9.91M	Buy	159,000 +78,000	+96%	+$6.13M	0.56%	60
2017 Q2	$6.45M	Hold	81,000	–	–	0.4%	63
2017 Q1	$5.76M	Sell	81,000 -89,000	-52%	-$5.21M	0.38%	69
2016 Q4	$8.68M	Hold	170,000	–	–	0.56%	57
2016 Q3	$7.83M	Hold	170,000	–	–	0.48%	59
2016 Q2	$5.12M	Hold	170,000	–	–	0.31%	73
2016 Q1	$5.45M	Buy	170,000 +44,100	+35%	+$1.55M	0.3%	72
2015 Q4	$7.34M	Buy	125,900 +6,700	+6%	+$332K	0.37%	66
2015 Q3	$5.04M	Buy	119,200 +79,000	+197%	+$4.87M	0.29%	73
2015 Q2	$2.94M	Hold	40,200	–	–	0.16%	90
2015 Q1	$2.02M	Hold	40,200	–	–	0.15%	94
2014 Q4	$1.47M	Hold	40,200	–	–	0.16%	88
2014 Q3	$1.27M	Buy	+40,200	New	+$1.16M	0.18%	86

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Eventide Asset Management's SAGE Position: Q2 2020 in Review

Eventide Asset Management sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 790,000 shares — an estimated $22.7M sold.

Eventide Asset Management first reported a position in SAGE in Q3 2014 and held it in 23 quarters. The position peaked at $138M in Q2 2019. 216 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

Eventide Asset Management reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
Eventide Asset Management sold 790,000 Sage Therapeutics shares in Q2 2020, an estimated $22.7M.
Eventide Asset Management first reported a position in Sage Therapeutics in Q3 2014 and held it in 23 quarters.
Eventide Asset Management's Sage Therapeutics position peaked at $138M in Q2 2019.
216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Eventide Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.